180P - Immunotherapy as an effective therapy approach for advanced non-small cell lung cancer (NSCLC): A single institution experience in the context of c...

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Immunotherapy
Non-Small Cell Lung Cancer
Therapy
Presenter Julia Martínez Pérez
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors J. Martínez Pérez1, A. Falcón González1, I. Sánchez Simón1, A. Cervera1, M. Alonso García1, M.J. Flor Oncala1, P. Maíquez2, I. Gallego Jiménez1, L. Jiménez González-Serna2, J. Corral1
  • 1Oncology, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 2Phase I Unit, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES

Abstract

Background

Lung cancer is the leading cause of cancer-related mortality globally with a 5-year survival rate 

Methods

Retrospective analysis of 61 patients with pretreated advanced NSCLC received anti-PD1 (programed cell death 1) and anti-PDL1 (programmed cell death-ligand 1) checkpoints inhibitors as expanded access treatment or as clinical trial therapy in our institution between 2013 and2015.

Results

61 patients were identified through an institutional therapy registry, including 80.3% males with a median age of 64 (range 35–85), 50.8% squamous histology and 9.8% never-smoker patients. Mutation profile was defined as negative EGFR/ALK in 95%; unknown PDL1 in 67.2% and positive PDL1 by inmunochemistry in 19 patients (31.1%). 63.9% of patients received anti-PD1 therapy vs 36.1% anti-PDL1 immune checkpoint inhibitors; 41% of patients received immunotherapy agents after two previous chemotherapy lines and 22.9% after 3 or more. With a median follow-up of 24 months (7–90.1), only ex- or active smokers had response to immunotherapy with an overall rate of 6.6% and disease control rate of 52.5% according to RECIST 1.1. No differences were seen between lines of therapy or immunotherapy strategies, but most of patients (51%) remain on treatment so survival rate were not reached. The most common grade I-II adverse events were fatigue (59%) and anorexia (23%) and pneumonitis grade III was observed in 16.4%.

Conclusions

Our data are consistent with recent immunotherapy results showing high disease control rate and durable clinical responses regardless of PDL1 status, PD-1/PDL-1 inhibition or line of therapy used, with manageable toxicity.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.